NCT06831409 Using CTA Measures to Define Cardiac Risk In NFL Alumni
| NCT ID | NCT06831409 |
| Status | Recruiting |
| Phase | — |
| Sponsor | HeartFlow, Inc. |
| Condition | Coronary Artery Disease (CAD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-12-17 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2024-12-17 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The GAMEFILM Registry is a post-market, multi-center, data collection study assessing the presence of CAD in NFL alumni.
Eligibility Criteria
Inclusion Criteria: * Retired NFL player Exclusion Criteria: * CCTA not successfully processed for FFRct and AI-Plaque
Contact & Investigator
Jeffrey Boone
PRINCIPAL INVESTIGATOR
Boone Heart Institute
Frequently Asked Questions
Who can join the NCT06831409 clinical trial?
This trial is open to participants of all sexes, studying Coronary Artery Disease (CAD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06831409 currently recruiting?
Yes, NCT06831409 is actively recruiting participants. Contact the research team at GAMEFILM@heartflow.com for enrollment information.
Where is the NCT06831409 trial being conducted?
This trial is being conducted at Greenwood Village, United States.
Who is sponsoring the NCT06831409 clinical trial?
NCT06831409 is sponsored by HeartFlow, Inc.. The principal investigator is Jeffrey Boone at Boone Heart Institute. The trial plans to enroll 300 participants.